On the board since 2016. Master of Business Administration from the Stockholm School of Economics, and also studied medicine at Karolinska Institutet. Experience: Anna has extensive experience in the healthcare industry, having worked as a McKinsey & Company consultant in the healthcare sector, as the Head of business development at Colonix Medical and as a project director at Scandinavian Health Partner. She is also a co-founder of healthcare companies Health Navigator AB and Aktiv Hälsostyrning i Sverige AB. Anna is currently serving as a board member of Ortivus AB (publ), ADDI Medical AB, WordDiagnostics AB and NRATIV AB. Anna Dalgaard owns 152,100 shares in Hemcheck. Dalgaard also indirectly controls 52,000 shares in Hemcheck. Independent in relation to the Company and the Group management. Independent in relation to the Company’s major shareholders.
Mathias Karlsson, is co-founder of Hemcheck Sweden AB. He has been a board member since 2022 but has previously been a board member in the company. Mathias is a medical doctor and has a doctoral thesis at Karolinska Institutet in the field of perinatal asphyxia. He is the CEO of the company Equalis, a supplier of systems for external quality assurance in laboratory medicine, imaging and functional medicine as well as patient-oriented analyses. Mathias Karlsson is also the founder and board member of Calmark. Mathias Karlsson is independent in relation to the company and company management and dependent in relation to larger ones shareholder. He holds 888,050 shares in the company.
On the board since 2010, and chaired the board between 2010 and 2015. Bachelor of Business Administration from Stockholm School of Economics. Hjalmar is a co-founder of Hemcheck, and of investment company Alfvén & Didrikson AB. He has broad international experience from the investment business: he has worked as a Senior Director at EQT (Stockholm and Warsaw) and previously also at FSN Capital Partners (Oslo) and UBS Investment Bank (London). Hjalmar Didrikson owns 881,380 shares in Hemcheck. He also indirectly controls 80,300 shares via Karlsson foundation and 3,266,445 shares as a co-owner of Stockholm Karlstad Invest. Independent in relation to the Company and the Group management. Dependent in relation to the Company’s major shareholders.
On the board since 2018. Biomedical analyst. Karin has more than 27 years of experience from management, marketing and sales in international medtech companies such as HemoCue AB, CellaVision AB, Bonesupport AB, Chromogenix AB in Sweden; EKF Diagnostics Ltd. in the UK; and Vida Care B.V. in the Netherlands. She is currently the CEO of Monivent AB, and a board member of Boule Diagnostics AB and Histolab Products AB. Karin Dahllöf owns 43,051 shares in Hemcheck. Independent in relation to the Company and the Group management. Independent in relation to the Company’s major shareholders.
